NeuroSense Therapeutics Ltd.
NRSN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875091
No open-market purchases or sales by NeuroSense Therapeutics Ltd. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $285.7K in total; no superinvestor holds it.
Other share classesNRSNW
Q1 2025 vs. Q4 2024
How the institutions holding NeuroSense Therapeutics Ltd. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 13 | 11 | −2 |
| Shares | 646.5K | 194.9K | −451.6K (−69.9%) |
| Value | $775.8K | $180.8K | −$595.1K (−76.7%) |
New holders (2)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Hurley Capital, LLC | 8,710 | $8.10K | 0.01% |
| UBS Group AG | 2,275 | $2.12K | 0.00% |
Sold out (4)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Citadel Advisors LLC | 253,997 | $304.8K |
| Jane Street Group, LLC | 64,636 | $77.6K |
| HRT Financial LP | 64,390 | $77.0K |
| Stratos Wealth Partners, LTD. | 20,000 | $24.0K |